The combination demonstrated greater incidence of grade 3–4 treatment-related side events, even in the face of an increasing trend in tumor mutational load [ 60 ].
← all excerpts
Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage.
1
—
—